Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effectiveness and Safety of Tramadol HCl/Acetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetic neuropathy in both lower extremities~* Lower extremity pain for at least 3 months~* Stable treatment of diabetes with drugs or diet for at least 3 months~* Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of \<10%)~* Documented daily pain on at least 4 of 7 days during baseline period (pain rated at least 5 on scale of 11)~* In generally good health~* If female of childbearing potential, using acceptable method of birth control~Exclusion Criteria:~* No failed trials of tramadol HCl or tramadol HCl/acetaminophen~* No participation in more than 2 clinical trials for treatment of neuropathic pain~* No more than 2 failed trials of medications for neuropathic pain~* No use of prohibited concomitant medications~* No peripheral neuropathy caused by condition other than diabetes~* No other pain more severe than neuropathic pain~* No progressive or degenerative neurological disorder~* No painful peripheral diabetic neuropathy for \> 10 years~* No kidney or liver dysfunction~* Not pregnant or breast-feeding~* No unstable medical disease~* No clinically significant medical conditions~* No condition that might affect the way the body absorbs or processes the study drug~* No history of suicide attempt/tendencies~* No major psychiatric disorder in past 6 months~* No history of drug or alcohol abuse/dependance in the past 2 years~* No amputations~* No active infection of the lower extremity~* No active foot ulcer~* No use of an investigational drug in past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).